Characterization of a commercial EPID-based in-vivo dosimetry and its feasibility and implementation for treatment verification in Malaysia Cover

.blurhash-client-img { display: none !important; }

Characterization of a commercial EPID-based in-vivo dosimetry and its feasibility and implementation for treatment verification in Malaysia

Polish Journal of Medical Physics and Engineering

Volume 28 (2022): Issue 4 (December 2022)

By: Yasmin Md Radzi, Azhar Abdul Rahman, Noor Naslinda Noor Rizan, Nur Nabilah Oskhahar and Nur Fatin Fariha Abd Latif

Open Access

|Dec 2022

Authors

Yasmin Md Radzi

yasminradzi@usm.my

School of Physics, Malaysia

Azhar Abdul Rahman

School of Physics, Malaysia

Noor Naslinda Noor Rizan

Department of Radiotherapy and Oncology, Gleneagles Medical Centre, Malaysia

Nur Nabilah Oskhahar

School of Physics, Malaysia

Nur Fatin Fariha Abd Latif

School of Physics, Malaysia

DOI: https://doi.org/10.2478/pjmpe-2022-0025 | Journal eISSN: 1898-0309 | Journal ISSN: 1425-4689

Journal RSS Feed

Language: English

Page range: 215 - 221

Submitted on: Jul 14, 2022

Accepted on: Dec 1, 2022

Published on: Dec 15, 2022

Published by: Polish Society of Medical Physics

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

EPID-based dosimetry,

patient-specific QA

Related subjects:

Biomedical engineering,

Technical and applied physics,

Medical physics

© 2022 Yasmin Md Radzi, Azhar Abdul Rahman, Noor Naslinda Noor Rizan, Nur Nabilah Oskhahar, Nur Fatin Fariha Abd Latif, published by Polish Society of Medical Physics
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 28 (2022): Issue 4 (December 2022)